Study of Denufosol Inhalation Solution in Patients With Mild to Moderate Cystic Fibrosis Lung Disease
Study of Denufosol Inhalation Solution in Patients With Mild to Moderate Cystic Fibrosis Lung Disease
The purpose of this trial is to evaluate the effects of a single dose of denufosol versus
 placebo on mucociliary clearance in patients with mild to moderate CF lung disease
Inclusion Criteria:

 -  have confirmed diagnosis of cystic fibrosis

 -  have FEV1 of greater than or equal to 60% of predicted normal for age, gender, and
 height

 -  be able to reproducibly perform spirometry maneuvers

 -  be clinically stable for at least 4 weeks prior to screening

 Exclusion Criteria:

 -  have abnormal renal or liver function

 -  have chest x-ray at screening with abnormalities suggesting clinically significant
 active pulmonary disease

 -  have had a lung transplant